☆ 4.7 Article

Gene Expression Profiling as a Novel Diagnostic Tool for Neurodegenerative Disorders

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline

Maria Pascual-Lucas et al.

Summary: This study investigates the ability of plasma A beta 42/A beta 40 ratio measured by an antibody-free mass-spectrometric method to detect early pathological changes of Alzheimer's disease (AD). The results show that plasma A beta 42/A beta 40 is significantly correlated with A beta-PET levels and can accurately identify individuals in the earliest stages of AD. Additionally, lower plasma A beta 42/A beta 40 ratio is associated with worse episodic memory performance and increased brain atrophy, and can predict clinical conversion to mild cognitive impairment and longitudinal changes in amyloid deposition and brain atrophy at 2-year follow-up.

ALZHEIMERS RESEARCH & THERAPY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Epigenetic Biomarkers as Diagnostic Tools for Neurodegenerative Disorders

Olaia Martinez-Iglesias et al.

Summary: This study aimed to identify epigenetic biomarkers for neurodegenerative diseases by analyzing DNA methylation, SIRT activity, and gene expression. The findings suggest that these biomarkers, which showed reduced levels in patients, could be useful for diagnosis, surveillance, and prognosis of neurodegenerative diseases.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Clinical Neurology

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques

Yan Li et al.

Summary: This study demonstrates that plasma A beta 42/A beta 40 assay is an accurate diagnostic tool for classifying amyloid PET status. The assay performs similarly in both cognitively unimpaired and impaired individuals, and its accuracy improves with APOE epsilon 4 carrier status.

NEUROLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Inferring protein expression changes from mRNA in Alzheimer's dementia using deep neural networks

Shinya Tasaki et al.

Summary: Identifying early protein changes in Alzheimer's dementia using deep neural network prediction of protein abundance from mRNA expression data can help identify potential drug targets.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Pharmacology & Pharmacy

Potential Protein Blood-based Biomarkers in Different Types of Dementia: A Therapeutic Overview

Patricia R. Manzine et al.

Summary: Research on blood-based biomarker proteins for diagnosing and distinguishing different types of dementia is important but limited. Updating blood biomarkers that can aid in the diagnosis and differentiation of dementia is crucial for developing specific pharmacological and clinical management strategies. Further studies are needed to identify exclusive biomarkers for each type of dementia before blood biomarkers can have valid use in clinical practice.

CURRENT PHARMACEUTICAL DESIGN (2022)

Add to Collection

Article Genetics & Heredity

New insights into the genetic etiology of Alzheimer's disease and related dementias

Celine Bellenguez et al.

Summary: By characterizing the genetic landscape of Alzheimer's disease and related dementias, new loci have been identified and a new genetic risk score associated with the risk of future Alzheimer's disease and dementia has been generated.

NATURE GENETICS (2022)

Add to Collection

Review Clinical Neurology

Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility

Thomas K. Karikari et al.

Summary: This article summarizes the performance of blood phosphorylated tau biomarkers in the context of Alzheimer disease (AD) and discusses the related ethical, analytical, and clinical challenges. It highlights the potential of blood biomarkers as first-line diagnostic and prognostic tools, but emphasizes the need to address outstanding ethical, clinical, and analytical challenges, and standardize inter-laboratory and inter-assay measurements.

NATURE REVIEWS NEUROLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Intronic enhancers of the human SNCA gene predominantly regulate its expression in brain in vivo

Fubo Cheng et al.

Summary: Evidence suggests that increased SNCA protein is a significant risk factor for Parkinson's disease (PD). This study identifies THAP1 and CTCF as transcription regulators of SNCA in the brain. SNCA intronic enhancers show neurodevelopment-dependent activities and form enhancer clusters enriched with PD-associated single-nucleotide polymorphisms. Deletion of these enhancer clusters reduces SNCA expression in the brain by preventing the release of paused RNA polymerase II from its promoter.

SCIENCE ADVANCES (2022)

Add to Collection

Review Cell Biology

PICALM and Alzheimer's Disease: An Update and Perspectives

Kunie Ando et al.

Summary: This article provides an overview of the current knowledge about the PICALM gene, including its physiological functions, genetic variants, post-translational modifications, and relevance to Alzheimer's disease pathogenesis.

CELLS (2022)

Add to Collection

Review Geriatrics & Gerontology

Is liquid biopsy mature enough for the diagnosis of Alzheimer's disease?

Xun Gong et al.

Summary: Liquid biopsy has made great progress in the preclinical diagnosis and clinical practice for Alzheimer's disease (AD). It provides a fast, low-cost, and easy way to diagnose AD and has led to the discovery of various biomarkers and a better understanding of the molecular pathogenesis of AD. However, the weighing of liquid biopsy reports for preclinical AD diagnosis remains an ongoing question.

FRONTIERS IN AGING NEUROSCIENCE (2022)

Add to Collection

Review Genetics & Heredity

Epigenetic Peripheral Biomarkers for Early Diagnosis of Alzheimer's Disease

Chiara Villa et al.

Summary: Alzheimer's disease is a progressive neurodegenerative disorder that leads to cognitive impairment and dementia in older individuals. Detection of altered epigenetic signatures in blood may assist in the early diagnosis and treatment of the disease.

GENES (2022)

Add to Collection

Review Genetics & Heredity

Alzheimer's Disease Connected Genes in the Post-Ischemic Hippocampus and Temporal Cortex

Ryszard Pluta

Summary: It is believed that brain ischemia is connected to Alzheimer's disease, as it causes deregulation of genes related to the disease in the hippocampus and temporal cortex. The changes in gene expression are more prominent in the CA1 region of the hippocampus compared to the CA3 region, and the temporal cortex shows immediate gene alterations after ischemia. This suggests that dysregulation of these genes is associated with neuronal responses in reversible cerebral ischemia.

GENES (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease

Liv Tybjaerg Nordestgaard et al.

Summary: Alzheimer's disease is the most common form of dementia, while vascular dementia is distinguished from Alzheimer's by previous stroke or hemorrhage evidence. Recent evidence suggests that controlling cardiovascular risk factors can reduce the risk of dementia. Factors such as body mass index, blood lipids, blood pressure, and diabetes have shared pathogenic pathways between dementia and cardiovascular disease.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Neurosciences

APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases

Rosalia Fernandez-Calle et al.

Summary: This article reviews the impact of the APOE genotype on late-onset Alzheimer's disease and central nervous system pathology, covering various factors influencing disease development, such as neuroinflammation, cell function, synaptic function, etc.

MOLECULAR NEURODEGENERATION (2022)

Add to Collection

Article Clinical Neurology

Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum

Alexis Moscoso et al.

Summary: Measurement of tau phosphorylated at threonine 181 (p-tau181) in blood plasma is proposed as a specific biomarker for Alzheimer's disease. Longitudinal study reveals that plasma p-tau181 increases before amyloid-beta markers reach abnormal levels, correlating with amyloid-beta pathology. Plasma p-tau181 also shows associations with widespread cortical tau aggregation and may be a useful diagnostic and screening tool for Alzheimer's disease.

BRAIN (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Expression Levels of an Alpha-Synuclein Transcript in Blood May Distinguish between Early Dementia with Lewy Bodies and Parkinson's Disease

Laura Marsal-Garcia et al.

Summary: Analysis of SNCA transcripts in LBD and control samples from temporal cortex as well as blood samples from DLB, PD, and control subjects showed overexpression of SNCAtv1 and SNCA112 in DLB, and SNCAtv2 in PD. Diminution of all SNCA transcripts was observed in DLB blood, with SNCAtv1 and SNCAtv2 diminished in PD in cases with disease onset before 70 years. SNCAtv3 showed decreased expression in early DLB and increased expression in early PD, indicating it could potentially be used as a biomarker for early DLB diagnosis.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Neurosciences

PICALM mRNA Expression in the Blood of Patients with Neurodegenerative Diseases and Geriatric Depression

Hiroshi Kumon et al.

Summary: This study found that PICALM mRNA expression in human blood was higher in patients with AD but lower in patients with PD, suggesting it may serve as a useful biomarker for differentiating neurodegenerative diseases and geriatric MDD.

JOURNAL OF ALZHEIMERS DISEASE (2021)

Add to Collection

Article Clinical Neurology

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

Shorena Janelidze et al.

Summary: This study highlights the potential of plasma P-tau217 as an early biomarker for Alzheimer's disease, showing elevated levels before tau-PET detected insoluble tau aggregates. Modeling suggests that changes in plasma and CSF P-tau217 precede tau-PET signals, indicating its usefulness in detecting early AD brain pathology.

JAMA NEUROLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Differentially expressed genes reflect disease-induced rather than disease-causing changes in the transcriptome

Eleonora Porcu et al.

Summary: Identification of gene expression changes between healthy and diseased individuals can reveal mechanistic insights and biomarkers. The bi-directional transcriptome-wide Mendelian Randomization approach was proposed to assess causal effects between gene expression and complex traits. Comparing transcript levels between healthy and diseased individuals allows for the identification of differentially expressed genes that may be causes, consequences or mere correlates of the disease under scrutiny.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Medicine, General & Internal

Parkinson's disease

Bastiaan R. Bloem et al.

Summary: Parkinson's disease is a neurodegenerative condition with diverse causes and clinical presentations. Diagnosis is clinically based, and treatment goals vary from person to person, emphasizing the need for personalized management. Currently, there is no therapy to slow down or arrest the progression of Parkinson's disease.

LANCET (2021)

Add to Collection

Review Geriatrics & Gerontology

Cholesterol, Atherosclerosis, and APOE in Vascular Contributions to Cognitive Impairment and Dementia (VCID): Potential Mechanisms and Therapy

Michael Tran Duong et al.

Summary: VCID is a common cause of cognitive decline, primarily caused by atherosclerosis leading to cerebrovascular disease and eventually neurodegeneration. Risk factors including hypercholesterolemia and hypertension promote atherosclerosis and carotid artery stenosis, disrupting cerebral blood flow and triggering ischemic strokes and VCID. The role of APOE, particularly APOE4, in lipid metabolism and chronic inflammation contributes to the pathogenesis of VCID.

FRONTIERS IN AGING NEUROSCIENCE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

APOE Genotype and Alzheimer's Disease: The Influence of Lifestyle and Environmental Factors

Efthalia Angelopoulou et al.

Summary: Alzheimer's disease is a common neurodegenerative disorder with complex pathogenesis and no disease-modifying therapy currently available. The interplay between genetic factors and environmental exposures, particularly the APOE gene alleles, may influence the risk of developing AD. Various lifestyle habits and environmental factors, such as physical exercise, dietary habits, and exposure to certain substances, have been shown to potentially interact with APOE alleles in affecting AD risk.

ACS CHEMICAL NEUROSCIENCE (2021)

Add to Collection

Article Clinical Neurology

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects

Joana B. Pereira et al.

Summary: Plasma biomarkers, particularly Aβ 42/40 and phosphorylated-tau217, can predict future Alzheimer's disease pathology in non-demented individuals, making them potential prognostic markers for clinical practice, research, and drug development.

BRAIN (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures

Sebastian Palmqvist et al.

Summary: Plasma P-tau, in combination with plasma phospho-tau and other biomarkers, along with clinical tests and APOE genotyping, can accurately predict the risk of Alzheimer's disease dementia, improving diagnostic prediction and facilitating recruitment for clinical trials.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Diagnostic and prognostic blood biomarkers in vascular dementia: From the viewpoint of ischemic stroke

Satoshi Hosoki et al.

Summary: Reliable blood biomarkers are crucial in the early diagnosis and therapeutic intervention of vascular dementia (VaD) and acute ischemic stroke (AIS). Both VaD and AIS share similar pathological conditions, and superior VaD blood biomarkers may be found among AIS blood biomarkers. Noncoding RNAs such as microRNA and long noncoding RNA, which can be analyzed using a single drop of blood, are particularly reliable VaD markers that reflect brain tissue damage.

NEUROCHEMISTRY INTERNATIONAL (2021)

Add to Collection

Article Multidisciplinary Sciences

Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations

Nicholas C. Cullen et al.

Summary: Plasma biomarkers of amyloid, tau, and neurodegeneration (ATN) can predict clinical deterioration in cognitively unimpaired elderly individuals. A combination of these biomarkers in plasma can reduce the required sample size in clinical trials, making them more feasible and cost-effective while improving efficacy.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Geriatrics & Gerontology

APP, PSEN1, and PSEN2 Variants in Alzheimer's Disease: Systematic Re-evaluation According to ACMG Guidelines

Xuewen Xiao et al.

Summary: The study systematically re-evaluated APP, PSEN1, and PSEN2 variants, showing that PSEN1 carried the most prevalent pathogenic/likely pathogenic variants, emphasizing the importance of interpreting these variants with caution according to ACMG-AMP guidelines.

FRONTIERS IN AGING NEUROSCIENCE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

DNA Methylation in Neurodegenerative and Cerebrovascular Disorders

Olaia Martinez-Iglesias et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Medicine, General & Internal

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

Sebastian Palmqvist et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Review Neurosciences

Alzheimer's Disease: The Link Between Amyloid-β and Neurovascular Dysfunction

Ernesto Solis et al.

JOURNAL OF ALZHEIMERS DISEASE (2020)

Add to Collection

Review Neurosciences

Exploring the Role ofPSENMutations in the Pathogenesis of Alzheimer's Disease

Md. Tanvir Kabir et al.

NEUROTOXICITY RESEARCH (2020)

Add to Collection

Article Public, Environmental & Occupational Health

Blood-brain barrier transcytosis genes, risk of dementia and stroke: a prospective cohort study of 74,754 individuals

Ida Juul Rasmussen et al.

EUROPEAN JOURNAL OF EPIDEMIOLOGY (2019)

Add to Collection

Review Clinical Neurology

The role of ABCA7 in Alzheimer's disease: evidence from genomics, transcriptomics and methylomics

Arne De Roeck et al.

ACTA NEUROPATHOLOGICA (2019)

Add to Collection

Article Genetics & Heredity

Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk

Iris E. Jansen et al.

NATURE GENETICS (2019)

Add to Collection

Article Genetics & Heredity

Association of PSEN1 rs165932 polymorphism with Alzheimer's disease susceptibility: An extensive meta-analysis

Akram R. S. Husain et al.

META GENE (2019)

Add to Collection

Review Neurosciences

Biomarkers for Alzheimer Disease: Classical and Novel Candidates' Review

Nadia El Kadmiri et al.

NEUROSCIENCE (2018)

Add to Collection

Article Clinical Neurology

A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease

Lasse Pihlstrom et al.

ANNALS OF NEUROLOGY (2018)

Add to Collection

Editorial Material Multidisciplinary Sciences

THE AMYLOID HYPOTHESIS ON TRAIL

Simon Makin

NATURE (2018)

Add to Collection

Review Pharmacology & Pharmacy

Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies

Filippo Ciceri et al.

CURRENT PHARMACEUTICAL DESIGN (2017)

Add to Collection

Review Cardiac & Cardiovascular Systems

Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review

Katrine Laura Rasmussen

ATHEROSCLEROSIS (2016)

Add to Collection

Review Biochemistry & Molecular Biology

Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance

Dena G. Hernandez et al.

JOURNAL OF NEUROCHEMISTRY (2016)

Add to Collection

Editorial Material Multidisciplinary Sciences

NEURODEGENERATIVE DISEASES

Marie-Therese Heemels

NATURE (2016)

Add to Collection

Article Multidisciplinary Sciences

The Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implication

Irum Javaid Siddiqui et al.

SCIENTIFIC REPORTS (2016)

Add to Collection

Article Clinical Neurology

Plasma Levels of Apolipoprotein E and Risk of Dementia in the General Population

Katrine L. Rasmussen et al.

ANNALS OF NEUROLOGY (2015)

Add to Collection

Article Neurosciences

OPRK1 promoter hypermethylation increases the risk of Alzheimer's disease

Huihui Ji et al.

NEUROSCIENCE LETTERS (2015)

Add to Collection

Article Neurosciences

Peripheral leukocyte expression of the potential biomarker proteins Bdnf, Sirt1, and Psen1 is not regulated by promoter methylation in Alzheimer's disease patients

Lucia Carboni et al.

NEUROSCIENCE LETTERS (2015)

Add to Collection

Article Multidisciplinary Sciences

Modulation of PICALM Levels Perturbs Cellular Cholesterol Homeostasis

Jacob L. Mercer et al.

PLOS ONE (2015)

Add to Collection

Article Neurosciences

The Role of PICALM in Alzheimer's Disease

Wei Xu et al.

MOLECULAR NEUROBIOLOGY (2015)

Add to Collection

Review Medicine, Research & Experimental

Biomarkers in vascular dementia: A recent update

Abhijeet Jagtap et al.

BIOMARKERS AND GENOMIC MEDICINE (2015)

Add to Collection

Review Neurosciences

Apolipoprotein E in Alzheimer's Disease: An Update

Jin-Tai Yu et al.

ANNUAL REVIEW OF NEUROSCIENCE, VOL 37 (2014)

Add to Collection

Article Neurosciences

ABCA7 expression is associated with Alzheimer's disease polymorphism and disease status

Jared B. Vasquez et al.

NEUROSCIENCE LETTERS (2013)

Add to Collection

Article Multidisciplinary Sciences

Alzheimer's Disease-Linked Mutations in Presenilin-1 Result in a Drastic Loss of Activity in Purified γ-Secretase Complexes

Matthias Cacquevel et al.

PLOS ONE (2012)

Add to Collection

Article Multidisciplinary Sciences

The PICALM Protein Plays a Key Role in Iron Homeostasis and Cell Proliferation

Paula B. Scotland et al.

PLOS ONE (2012)

Add to Collection

Article Genetics & Heredity

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease

Paul Hollingworth et al.

NATURE GENETICS (2011)

Add to Collection

Letter Biochemistry & Molecular Biology

Common mechanisms in neurodegeneration

Jesus Avila

NATURE MEDICINE (2010)

Add to Collection

Review Clinical Neurology

LRRK2 and neurodegeneration

Gabriel Santpere et al.

ACTA NEUROPATHOLOGICA (2009)

Add to Collection

Article Pathology

Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research

Kjetil Soreide

JOURNAL OF CLINICAL PATHOLOGY (2009)

Add to Collection

Article Neurosciences

Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels

David R. Riddell et al.

JOURNAL OF NEUROSCIENCE (2008)

Add to Collection

Article Clinical Neurology

Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients

Ornit Chiba-Falek et al.

MOVEMENT DISORDERS (2006)

Add to Collection

Review Hematology

Brain cholesterol:: Long secret life behind a barrier

I Björkhem et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)

Add to Collection

Article Geriatrics & Gerontology

Reduced expression of amyloid precursor protein, presenilin-1 and rab3a in cortical brain regions in Alzheimer's disease

P Davidsson et al.

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.